Business
Results of General Meeting
Allergy Therapeutics plc announced that all resolutions were passed at its General Meeting, including the authorization for directors to allot shares up to a nominal amount of £610,000 and to disapply pre-emption rights. These approvals are to facilitate a potential equity raise, which could involve issuing up to 610,000,000 new ordinary shares, approximately 10% of the current issued share capital. The company also posted its Annual Report and Accounts for the year ended 30 June 2025 to shareholders. Disclaimer*
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\")\n \nResults of General Meeting and Posting of Annual Report 2025\n \n29 December 2025 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, announces that at the General Meeting held today, all resolutions were duly passed.\n \nResults of General Meeting\n \nAll resolutions at the General Meeting were voted on by way of a poll. The results of the poll were as follows:\n \n\n\n\n\nResolution\n\n\nFor\n\n\n%\n\n\nAgainst\n\n\n%\n\n\nTotal Votes Cast\n\n\nWithheld\n\n\n\n\nOrdinary Resolution\n\n\n\n\n1. To authorise the directors to allot shares and to grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of £610,000.00\n\n\n5,813,451,109\n \n\n\n99.98\n\n\n903,088\n \n\n\n0.02\n\n\n5,814,354,197\n \n\n\n1,210\n \n\n\n\n\nSpecial Resolution\n\n\n\n\n2. To disapply pre-emption rights in respect of an allotment of equity securities for cash pursuant to the authority granted by Resolution 1\n\n\n5,810,471,464\n \n\n\n99.93\n \n\n\n3,882,733\n \n\n\n0.07\n \n\n\n5,814,354,197\n \n\n\n1,210\n \n\n\n\n\nThe General Meeting was held as the Board is considering potentially undertaking an equity raise which would be structured by issuing New Shares to new investors and/or existing shareholders in the Company for cash consideration in one or more private placements on a non-pre-emptive basis (the \"Potential Equity Raise\").\nIn order to facilitate the Potential Equity Raise and to ensure that it could be swiftly concluded if it progresses, the Board sought and, at the General Meeting, obtained, shareholder approval for the allotment and issue of up to 610,000,000 ordinary shares of £0.001 each (\"New Shares\") (which is approximately 10% of the Company's current issued share capital) on terms that the Board may determine. In order for the Directors to issue New Shares free of statutory pre-emption rights, such statutory pre-emption rights must be dis-applied. Accordingly, the Board sought, and, at the General Meeting, obtained, shareholder approval to dis-apply pre-emption rights in respect of th...